Furthermore, treatment of the R6/2 mouse model of HD with a DRP-1 inhibitor (P110-Tat) improved behavior, survival and neuropathology in these mice, and resulted in a significant increase in cristae area in electron micrographs [19]. Here, DNM1L is linked to Huntington disease.